Skip to main content
Sign In

RMADC Presents at Key International Alzheimer's Disease Conference

Six teams present

Six research teams from the Rocky Mountain Alzheimer’s Disease Center (RMADC) presented their recent research findings — spanning a wide range of topics — at the 2018 Alzheimer’s Association International Conference® (AAIC) in Chicago July 22–26. Many RMADC members played key roles in more than one of these projects, showing our innovative spirit and our commitment to engaging in strong team science that will help us prevent, diagnose and treat the many forms of dementia.

GM-CSF/Leukine® Talks and Posters

RMADC Director Huntington Potter, PhD, gave a platform presentation sharing an update on data from the Phase II human trial to determine the safety and efficacy of GM-CSF/Leukine® in mild-to-moderate Alzheimer’s disease (AD). RMADC co-authors include Drs. Jonathan Woodcock, Timothy Boyd, Stefan Sillau, Thomas Borges, Brianne Bettcher and Ashesh Thaker, as well as Ramesh Karki, Joseph Daniels and Kate Heffernan. Dr. Timothy Boyd presented a poster describing blood biomarker changes in subjects from the Phase II GM-CSF/Leukine® trial, as well as investigation into whether the Leukine®-associated changes in biomarker levels also correlate with brain or symptom changes associated with AD. RMADC co-authors include Drs. Potter, Woodcock, Sillau, Borges, and Bettcher, together with Vanesa Adame, Joseph Daniels and Kate Heffernan.

Dr. Md. Mahiuddin Ahmed presented a poster showing his finding that GM-CSF treatment can reverse some of the memory deficits in a mouse model of Down syndrome; RMADC co-authors include Drs. Huntington Potter, Athena Ching Jung Wang, Timothy Boyd and Mihret Elos.

Convergence Insufficiency

Drs. Samantha Holden and Victoria Pelak presented a poster focused on the relationships between cognitive impairment, subjective visual symptoms, and objectively measured “convergence insufficiency”, which is a term used to describe an inability to coordinate binocular eye movements to maintain single vision during near target viewing and is most often reported by patients as double vision, in patients with Parkinson’s disease. 

Performance-Based Assessments

Dr. Luis Medina presented a poster describing his pilot study using three performance-based functional assessments in normal aging and mild cognitive impairment subjects to determine the sensitivity of daily function assessments to detect age- and Alzheimer’s-related brain changes. RMADC co-authors include Drs. Brianne Bettcher and Chris Filley, together with Kate Heffernan.

Aneuploidy in Huntington's disease

Mihret Elos, M.S., presented a poster showing that brain cells and fibroblast cell lines from Huntington’s disease patients show elevated levels of aneuploidy (abnormal numbers of chromosomes). RMADC co-authors include Drs. Julbert Caneus, Heidi Chial and Huntington Potter.

Odor Recognition for Predicting Decline

Dr. Peter Pressman presented a poster describing his studies of whether odor recognition — using ground coffee as a non-standardized, inexpensive, readily available and reusable odor — may be useful for predicting cognitive decline. RMADC co-authors include Drs. Jonathan Woodcock and Chris Filley.

Having so many RMADC team members presenting at this key conference underscores the international scientific community’s interest in the work we are doing, and in the insights this research will add to our global understanding of these dementing diseases.​